Objective:To investigate the relationship between SET domain bifurcated 1(SETDB1)expression and trefoil factor 1(TFF1)gene methylation,along with its clinical significance.Methods:Fifty-five lung adenocarcinoma samples and normal tissues of distant cancer were collected from the Affiliated Hospital of Chengde Medical College Hebei Province.TFF1 gene methylation levels were measured by pyrosequencing,relative TFF1 mRNA expression was assessed using quantitative real-time polymerase chain reaction(qRT-PCR),and TFF1 and SETDB1 protein expression were quantified via immunohistochemistry.The clinical significance and correlation between TFF1 methyla-tion levels and SETDB1 protein expression were analyzed statistically.In vitro,SETDB1 siRNA or negative control siRNA was transfected into A549 cells.Following transfection,SETDB1 mRNA expression was analyzed using qRT-PCR,and SETDB1 protein expression was evaluated via Western blot.TFF1 methylation was reassessed via pyrosequencing.Results:In lung adenocarcinoma and normal tissues of distant cancer,TFF1 gene methylation rates were(70.16±6.32)%and(12.46±2.22)%,respectively.TFF1 mRNA relative expression levels were 0.56±0.17 for cancer tissues and 1.56±0.22 for the normal tissues of distant cancer.All detected differences were statistically significant(all P<0.05).TFF1 protein expression rates were 29.09%(16/55)for cancer tissues and 65.45%(36/55)for the normal tissues of distant cancer.Additionally,relative positivity rates for SETDB1 protein expression were 74.55%(41/55)and 23.64%(13/55),respectively,and all differences were stat-istically significant(all P<0.05).Western blot analysis showed that SETDB1 protein expression was significantly higher in cancer tissues(72.89±5.27)%,compared to normal tissues of distant cancer(24.27±2.37)%.In contrast,TFF1 protein expressed was markedly lower in can-cer tissues(15.38±2.33)%than in normal tissues of distant cancer(72.72±4.48)%.All differences were statistically significant(all P<0.05).TFF1 methylation and SETDB1 expression were associated with lung adenocarcinoma(r=0.486,P<0.05).Both TFF1 methylation and SETDB1 expression were closely associated with tumor TNM stage,tissue differentiation,and lymph node metastasis(P<0.05).Furthermore,TFF1 methylation increased following SETDB1 downregulation(P<0.05).Conclusions:During lung adenocarcinoma progression,SETDB1 expres-sion correlates with TFF1 methylation,and the highly expressed SETDB1 may play a role in catalyzing TFF1 methylation.

Multiple myeloma(MM)is a malignancy characterized by the abnormal proliferation of clonal plasma cells.It is often associated with coagulation abnormalities,posing risks of thrombosis,thromboembolism,and bleeding,including severe cases,which are related to de-creased quality of life,delayed or discontinued treatment,and reduced survival.Disease,individual-specific factors,and therapeutic agents affect the dynamic balance of coagulation,anticoagulation,and fibrinolytic systems in patients with MM.The diagnosis and treatment of un-derlying coagulation disorders are challenging due to the involvement of multiple mechanisms.In addition,newly introduced therapies such as immunomodulatory drugs,proteasome inhibitors,chimeric antigen receptor-modified T-cell therapy,and monoclonal antibodies also im-pact coagulation in patients with MM.This review discusses the influencing factors,pathophysiological mechanisms,and prevention and treatment strategies for coagulation abnormalities in MM.

Peritoneal mesothelioma(PeM),which originates in cells in the visceral and mural layers of the peritoneum,is a rare and highly aggressive malignant tumor that accounts for approximately 15%of all mesotheliomas.The disease is characterized by insidious onset and poor prognosis,and its mechanisms of tumorigenesis and progression have not been fully elucidated.Asbestos exposure is a major risk factor for mesothelioma.Effective treatment options alternative to cytoreductive surgery(CRS),hyperthermic intraperitoneal chemotherapy(HIPEC),and platinum/pemetrexed(conventional treatments)are currently lacking.Immunotherapy,which mobilizes the immune system,has shown initial efficacy in patients with advanced mesotheliomas.However,additional real-world clinical trials and studies on immuno-therapeutic targets remain needed.This article reviews progress in PeM-related immunotherapy clinical studies and potential targets in PeM treatment.

Objective:To actively screen the dynamic colonization of Enterobacteriaceae in the gastrointestinal tract of tumor patients and explore the homology between carbapenem-resistant Enterobacteriaceae(CRE)colonized in the gastrointestinal tracts of these patients and the bacteria causing bloodstream infections,to provide meaningful reference data for diagnosis and treatment by clinicians.Methods:A total of 32 strains of gram-negative bacilli were isolated from 353 intestinal specimens of tumor patients at The First Affiliated Hospital of Henan University of Science and Technology from December 2021 to November 2022.The bacterial identification instruments VITEK 2 Com-pact,a carbapenemase detection kit using colloidal gold immunochromatography,and polymerase chain reaction(PCR)were used to de-tectdrug resistance genes and phenotypes.Pulsed-field gel electrophoresis(PFGE)was used to analyze and compare the homology between CRE strains in the intestinal tract of patients and pathogenic microorganisms causing bloodstream infections.Results:Among the 32 strains of Gram-negative bacilli screened from the gastrointestinal tract of cancer patients,6 strains(1.6%,6/353)were carbapenem-resistant Kleb-siella pneumoniae(CRKp).All six CRKp strains harbored blaKPC gene.The proportion of CRE is 3.3%(12/353).Bloodstream infection oc-curred in 2 patients with intestinal colonization of Klebsiella pneumoniae,which was caused by the same CRKp strain as intestinal coloniza-tion.Conclusions:The proportion of CRE intestinal colonization in tumor patients was not high;however,under certain circumstances,CRE colonized in the intestines of tumor patients can cause ectopic infections else where in the body,including the bloodstream,which should be closely monitored.The findings indicate the importance of increased attention to critically ill patients who have undergone multiple hospital-izations with long hospitalization times,as well as early screening for intestine-colonizing microorganisms and rational regulation of the anti-biotic usage.

Objective:To explore the relationship between basic transcription factor 3(BTF3)and glioblastoma multiforme(GBM)cell migra-tion,invasion,and proliferation.Methods:The expression levels of BTF3 in GBM tissues were analyzed using The Cancer Genome Atlas(TCGA),Gene Expression Profiling Interactive Analysis 2(GEPIA2),and The University of ALabama at Birmingham CANcer data analysis Portal(UALCAN)online databases.The effects of inhibiting BTF3 on the malignant biological properties of GBM cells were assessed using the cell scratch,plate colony formation,Cell Counting Kit(CCK)-8,and Transwell assays,and the effect of BTF3 knockdown on Janus kinase 2/signal transducer and activator of transcription 3(JAK2/STAT3)signaling pathway-related protein expression levels in GBM cells was determined using Western blot.In addition,GBM cells stably transfected with KD-BTF3 were subcutaneously injected into nude mice,and tumor sizes were analyzed.Western blot was performed to verify the expression of JAK2/STAT3 signaling pathway-related proteins in the tumor tissues.Results:1)BTF3 was highly expressed in GBM cells.2)After BTF3 knockdown,the malignant biological properties of GBM cells were signific-antly decreased.3)After BTF3 knockdown,phosphorylated(p)-JAK2 and p-STAT3 expressions were downregulated,JAK2 and STAT3 expres-sions were unchanged,and p21 expression was increased.4)BTF3 knockdown inhibited GBM tumorigenesis.Therefore,the expression of JAK2/STAT3 signaling pathway-related proteins was consistent with the in vitro results.Conclusions:BTF3 is highly expressed in GBM and regulates the proliferation,migration,and invasion of GBM cells through the JAK2/STAT3 signaling pathway.

Objective:To observe the longitudinal changes of symptoms in the irradiation area of patients with postoperative radiotherapy for breast cancer,and investigate the correlative symptom indexes for predicting acute radiation dermatitis during radiotherapy.Methods:This study was designed as a prospective longitudinal study.A total of 103 patients with breast cancer who received three-dimensional con-formal radiotherapy in The Fourth Hospital of Hebei Medical University from May 2022 to December 2022 were enrolled using convenience and purposive sampling methods.The patients received a total of 50 Gy/25 radiotherapy sessions.We conducted weekly observations of five symptoms-itching,pain,swelling,burning,and tightness-in the irradiated area,for a total of six weeks.The incidence of symptoms associ-ated with radiation dermatitis across different severity levels was compared.We calculated the optimal number of symptoms for the occur-rence of grade 2 or higher radiation dermatitis,evaluated the predictive effect using the subject's work characteristic curve(ROC),and com-pared the risk of radiation dermatitis with the number of symptoms by applying a binary Logistic regression.Results:A total of 103 patients were included in the study.The total severity scores of symptoms were 0(0,0),0(0,0),0(0,1),1(0,2),2(1,3),3(2,4),respectively,show-ing a gradually increasing trend.From the 20 Gy/10-fraction radiotherapy point onward to the completion of radiotherapy,symptom scores exhibited statistically significant deviations from baseline values(P<0.001).From the beginning of 30 Gy/15 sessions to the end of radiother-apy,symptom scores were higher in patients with grade 2 and above dermatitis compared to those with dermatitis of less than grade 2(Z=2.12,2.81,4.08,P=0.034,0.005,0.001);at the end of 50Gy/25 sessions,the incidence rates of pruritus,pain,swelling,tightness,and burning were 68.9%(71 cases),68.9%(71 cases),46.6%(48 cases),36.9%(38 cases),and 15.5%(16 cases),respectively.At the 30 Gy/15 and 40 Gy/20 radiotherapy sessions,the optimal number of predicted symptoms were two and three,respectively.The corresponding areas under the ROC curve were 0.632 and 0.666.Sensitivity values were 48.6%and 43.2%,while specificity values reached 77.3%and 81.8%,re-spectively(95%CI:0.517-0.746,0.558-0.775,P=0.027,0.005).The subjects were assigned into low-risk and high-risk groups using the op-timal cut-off values,and binary Logistic regression showed that the risks of grade 2 and higher radiation dermatitis in the high-risk group were 3.39 and 3.58 times higher than that in the low-risk group(OR=3.388,95%CI:1.400-8.197,P=0.007;OR=3.584,95%CI:1.430-8.985,P=0.006).Conclusions:The symptoms of radiation dermatitis have appeared early and worsened with the severity of dermatitis.We should closely observe these symptoms throughout treatment.The risk of grade 2 and above radiation dermatitis increased when the number of symptoms was≥2 at 30 Gy/15 times and≥3 at 40 Gy/20 times.

As the application of immune checkpoint inhibitors(ICIs)in the perioperative treatment of melanoma is increasingly introduced at earlier stages,it presents a critical opportunity for the development and clinical translation of neoadjuvant therapy.The results of phaseⅠ/Ⅱ clinical trials on neoadjuvant ICI therapy for melanoma demonstrate that neoadjuvant ICIs effectively improve the pathologic re-sponse rate in melanoma patients.Recent studies have shown that combining ICIs with other treatment modalities,including radiotherapy,chemotherapy,and targeted therapies,can enhance antitumor efficacy of neoadjuvant treatment for patients with melanoma.Optimizing treatment regimens,managing adverse events,identifying and addressing pseudoprogression,and handling cases of oligoprogression have become key areas of research in incorporating ICI regimens into neoadjuvant treatment for patients with melanoma.The search for bio-markers to monitor immunotherapy efficacy is expected to become a major focus of future research.This article provides a review of the re-search progress,controversies,and challenges in the application of ICIs in the neoadjuvant treatment of melanoma,and discusses future re-search directions,aiming to offer insights into the clinical application and development of ICIs in melanoma neoadjuvant therapy.

Immunotherapy has recently shown significant potential in treating malignant tumors.However,the immunosuppressive nature of the tumor microenvironment(TME)limits the number of patients who benefit from this approach.Combining ultrasound with drug-loaded microbubble technology can directly induce tumor cell death through cavitation and pore-forming effects;this promotes tumor anti-gen presentation and enhances immune recognition of these antigens.This strategy also modulates the immunosuppressive state of the tu-mor microenvironment,making it more conducive to an effective immune response.It also normalizes blood vessels and reduces interstitial fluid pressure within the tumor,as well as helps therapeutic agents or genes to penetrate tumor tissues,thereby enhancing overall immune efficacy.This review examines the use of low-intensity ultrasound combined with drug-loaded microbubbles to improve the tumor microen-vironment and boost tumor immune responses.

Colorectal cancer(CRC)is one of the most common malignant tumors worldwide,and its incidence and fatality rates rank at the forefront of malignant tumors.In recent years,with the maturity of laparoscopic and robotic technology,and the application of new staplers,the efficacy and safety of surgery for CRC have improved;however,postoperative complications still seriously affect postoperative quality of life and survival time.Identification of nutritional predictors of CRC is conducive to the early identification of high-risk patients,reinforce-ment of individualized care,enhancement of the quality of peri-operative management,reduction in the incidence of postoperative complic-ations,and improvement of the short-and long-term prognosis.In this paper,the literature on nutritional predictors of postoperative com-plications of CRC was reviewed,the evaluation contents and efficacy of nutritional predictors were summarized,and their advantages and disadvantages were analyzed.The aim is to provide a reference for identifying nutritional predictors of postoperative complications of CRC that are readily accessible,low-cost,and adjustable pre-operatively.

This review summarizes recent advances in neoadjuvant immunotherapy for advanced gastric cancer.Through literature search in PubMed,Web of Science,and CNKI databases from 2020 to 2023,we systematically analyzed the mechanisms,clinical applications,and bio-marker research.Programmed death-1(PD-1)inhibitors combined with chemotherapy significantly improve patient outcomes,while mi-crosatellite instability(MSI),programmed death-ligand 1(PD-L1)expression,and tumor mutational burden(TMB)have been identified as important predictive biomarkers.Multi-omics analysis shows great potential in identifying optimal responders,with pyroptosis-related gene scoring system(PRS)positively correlating with anti-tumor immune infiltration.Metabolic reprogramming and epigenetic regulation in the tumor microenvironment play key roles in immune evasion,while emerging targets such as Claudin 18.2 and combination targeting strategies further enhance therapeutic efficacy.Despite significant progress,precise patient selection and overcoming resistance mechan-isms remain major challenges.Future research should focus on biomarker validation,personalized treatment strategy development,tumor microenvironment dynamic analysis,and novel combination therapy exploration to improve clinical outcomes.